NCT06113315Enrolling by invitation
A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy
An Observational Study of Sarcoma Patients Treated With Immunotherapy at Memorial Sloan Kettering Cancer Center
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 27 Oct 2023
- Start date
- 27 Oct 2023
- Primary completion date
- Oct 2028
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT06113315
What you commit to
- Study type: Observational
- Planned participants: 250
- From 27 Oct 2023 to the primary completion date, Oct 2028
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to ICB or ACT initiation), during, and after ICB or ACT treatment
Who the study is looking for
- Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist.
- Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy OR any prospectively identified patient being treated or to be treated with ACT-based treatment including but not limited to lifileucil, Afamitresgene autoleucel, and letetresgene autoleuce o Novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) Please Note: there is no age requirement. Patients of all ages are eligible to enroll
Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) Coordinator of this site? Confirm its status | Commack | United States | Unknown status |
| Memorial Sloan Kettering Westchester (All Protocol Activities) Coordinator of this site? Confirm its status | East White Plains | United States | Unknown status |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen (All Protocol Activities) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Nassau (All Protocol Activities) Coordinator of this site? Confirm its status | Uniondale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.